Literature DB >> 19605955

Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice.

Krzysztof Bryniarski1, Marian Szczepanik, Maria Ptak, Magdalena Zemelka, Włodzimierz Ptak.   

Abstract

2,4,6-Trinitrophenyl (TNP) hapten-labeled peritoneal macrophages (Mf) given intravenously (iv) to recipients are poor inducers of contact sensitivity (CS) reactions unless Mf donors are pretreated with low doses of cyclophosphamide (CY). In vivo CY is converted into active alkylating metabolites, phosphoramide mustard (PM) and acrolein (ACR). Our experiments aimed to test how in vitro treatment of non-immunogenic Mf with different concentrations (10(-5) to 10(-7) M) of CY metabolites will influence their immunogenicity and other biological functions. Instead of chemically unstable PM, we used structurally and functionally similar nitrogen mustard (NM). Our experiments show that treatment of Mf with ACR or NM stimulates the in vitro production of pro-inflammatory IL-6 and IL-12 and down-regulates anti-inflammatory IL-10 and TGF-beta cytokines. In vivo non-immunogenic TNP-Mf become capable of inducing CS reactions in two situations: first, after treatment with NM or ACR and second, when cell recipients are received iv before Mf transfer of monoclonal antibodies against IL-10 and/or TGF-beta (500 mug per animal). Treatment with NM, but not with ACR, was also an efficient stimulus for production by Mf of significantly increased levels of reactive oxygen intermediates (ROIs). In summary, our experiments show that CY metabolites can significantly increase the specific immune response as well as nonspecific innate reaction (ROIs production) and support the notion that CY and its metabolites can be a promising accessory tool when upregulation of the immune response is desired.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605955     DOI: 10.1016/s1734-1140(09)70098-2

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  16 in total

Review 1.  Adapting conventional cancer treatment for immunotherapy.

Authors:  Jian Qiao; Zhida Liu; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2016-02-24       Impact factor: 4.599

Review 2.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

Review 3.  Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).

Authors:  Olga V Zhukova; Tatiana F Kovaleva; Evgenia V Arkhipova; Sergey A Ryabov; Irina V Mukhina
Journal:  Biomed Rep       Date:  2020-08-28

4.  Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts.

Authors:  A B Farris; D Taheri; T Kawai; L Fazlollahi; W Wong; N Tolkoff-Rubin; T R Spitzer; A J Iafrate; F I Preffer; S A Locascio; B Sprangers; S Saidman; R N Smith; A B Cosimi; M Sykes; D H Sachs; R B Colvin
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

5.  Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8⁺ cell-derived exosomes.

Authors:  Katarzyna Nazimek; Wlodzimierz Ptak; Bernadeta Nowak; Maria Ptak; Philip W Askenase; Krzysztof Bryniarski
Journal:  Immunology       Date:  2015-04-27       Impact factor: 7.397

Review 6.  The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.

Authors:  Daniel R Principe; Suneel D Kamath; Murray Korc; Hidayatullah G Munshi
Journal:  Pharmacol Ther       Date:  2022-01-10       Impact factor: 13.400

7.  Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.

Authors:  Terry R Medler; Tiziana Cotechini; Lisa M Coussens
Journal:  Trends Cancer       Date:  2015-09-01

Review 8.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

9.  Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?

Authors:  Antonino C Tralongo; Roberto S Fratamico; Chiara Russo; Andrea Sbrana; Andrea Antonuzzo; Marco Danova
Journal:  Geriatrics (Basel)       Date:  2021-04-15

Review 10.  Chemotherapy: a double-edged sword in cancer treatment.

Authors:  Nafiseh Behranvand; Farzad Nasri; Reza Zolfaghari Emameh; Pouria Khani; Asieh Hosseini; Johan Garssen; Reza Falak
Journal:  Cancer Immunol Immunother       Date:  2021-08-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.